Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
225 mg: for a 10 mg dose 6 months, or for those on even higher doses
Individuals with type 2 diabetes were excluded from this particular trial, meaning the results reflect outcomes in adults with obesity or overweight but without diabetes
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) not yet licensed by the MHRA or EMA for use in the UK
Summary: 'Ozempic breasts' refers to breast changessuch as reduced volume, altered firmness, or saggingthat occur as a natural consequence of weight loss in patients taking Ozempic (semaglutide), rather than a direct drug effect
US$ 29.74
US$ 25.85
US$ 28.83
US$ 24.00
US$ 21.51
US$ 26.26
US$ 22.76
US$ 24.28
